Cancer Drug Resistance indexed in PubMed Central

On May 17, 2022, Cancer Drug Resistance (CDR, 2578-532X (Online)), an OAE journal, passed the scientific quality review process of the U.S. National Institutes of Health's National Library of Medicine (NIH/NLM), and is now officially indexed in PubMed Central® (PMC). This will greatly enhance the international influence of CDR.

PMC is a free full-text archive of biomedical and life sciences journal literature at the U.S. National Institutes of Health's National Library of Medicine (NIH/NLM).

PMC implements strict requirements for indexed journals. Journals that pass the quality review process need to meet two standards: Scientific Quality Standard and Technical Requirements. For CDR, being indexed in PMC is not only an affirmation of the academic quality of the published articles, but also an affirmation of the efforts of the Editor-in-Chief, Editorial Board members, authors, and reviewers. In addition to the retrospective indexed publications, all CDR publications will be displayed in full text on PMC after May 2022, and abstracts can also be retrieved on PubMed.

CDR Editorial Office would like to express our sincere thanks to all authors, reviewers, Editorial Board members, and readers for their support. In the future, CDR Editorial Office will control the publication quality with higher standards, and strive to make CDR an internationally influenced academic journal in the field of cancer drug resistance.

PMC page: https://www.ncbi.nlm.nih.gov/pmc/journals/4180/

Welcome to follow and contribute to CDR
CDR supports golden open access publishing. All articles are free for readers to download and read.
Homepage: https://oaepublish.com/cdr
Contact us: editorial@cdrjournal.com